Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC
Clinical trial NCT06061146 · RECRUITING
Trial details
- NCT number
- NCT06061146
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-05
- Primary completion
- 2024-10-01
- Enrollment
- 136
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.